Genetic Technologies Ltd

3.79-0.0600-1.56%Vol 351.25K1Y Perf 101.07%
Apr 20th, 2021 16:00 DELAYED
BID3.79 ASK3.82
Open3.83 Previous Close3.85
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.13
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap56.96M 
Earnings Rating
Neutral
Price Range Ratio 52W %
23.86 
Earnings Date
4th Sep 2020

Today's Price Range

3.673.85

52W Range

1.7510.30

5 Year PE Ratio Range

-2.20-4.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.33%
1 Month
-18.14%
3 Months
-30.84%
6 Months
11.47%
1 Year
101.07%
3 Years
-28.22%
5 Years
-61.33%
10 Years
-94.10%

TickerPriceChg.Chg.%
GENE3.79-0.0600-1.56
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
14.30
14.60
0.01
0.02
-460.50
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-833.50
-26 877.70
-26 877.70
-18 523.60
-
RevenueValueIndustryS&P 500US Markets
19.97K
0.00
-56.15
-53.86
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume351.25K
Shares Outstanding15.03M
Trades Count1.16K
Dollar Volume2.80M
Avg. Volume1.92M
Avg. Weekly Volume357.50K
Avg. Monthly Volume1.58M
Avg. Quarterly Volume2.05M

Genetic Technologies Ltd (NASDAQ: GENE) stock closed at 3.79 per share at the end of the most recent trading day (a -1.56% change compared to the prior day closing price) with a volume of 352.71K shares and market capitalization of 56.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 13 people. Genetic Technologies Ltd CEO is Jerzy Muchnicki.

The one-year performance of Genetic Technologies Ltd stock is 101.07%, while year-to-date (YTD) performance is 5.28%. GENE stock has a five-year performance of -61.33%. Its 52-week range is between 1.75 and 10.3, which gives GENE stock a 52-week price range ratio of 23.86%

Genetic Technologies Ltd currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 4.34, a price-to-sale (PS) ratio of 2 897.94, a price to cashflow ratio of 19.30, a PEG ratio of 2.32, a ROA of -59.74%, a ROC of -65.60% and a ROE of -68.10%. The company’s profit margin is -%, its EBITDA margin is -26 877.70%, and its revenue ttm is $19.97 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Genetic Technologies Ltd, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genetic Technologies Ltd’s next earnings report date is -.

The consensus rating of Wall Street analysts for Genetic Technologies Ltd is (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Genetic Technologies Ltd stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genetic Technologies Ltd has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genetic Technologies Ltd has a Sell technical analysis rating based on Technical Indicators (ADX : 24.47, ATR14 : 0.43, CCI20 : -156.87, Chaikin Money Flow : -0.48, MACD : -0.22, Money Flow Index : 86.60, ROC : -13.47, RSI : 34.62, STOCH (14,3) : 7.58, STOCH RSI : 0.00, UO : 41.55, Williams %R : -92.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genetic Technologies Ltd in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Genetic Technologies Ltd

Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.

CEO: Jerzy Muchnicki

Telephone: +61 384127000

Address: 60-66 Hanover Street, Melbourne 3065, VIC, AU

Number of employees: 13

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

73%27%

News

Stocktwits